Literature DB >> 18708312

[Rasburicase therapy may cause hydrogen peroxide shock].

László Góth1.   

Abstract

Hyperuricemia contributes to the pathomechanism of diseases such as renal failure, gout, tumor lysis syndrome and metabolic syndrome. Tumor lysis syndrome is a complication of malignancies caused by massive tumor cell lysis due to either spontaneous tumor cell lysis or to different therapies and it may cause hyperuricemia. Recently, for treatment of hyperuricemia the recombinant urate oxidase (rasburicase) therapy has been used. This enzyme converts uric acid with high affinity into soluble allantoin which is eliminated by the kidneys. In this reaction high concentration of hydrogen peroxide is generated. This hydrogen peroxide could cause hemolysis and especially methemoglobin formation, in case of glucose-6-phosphate-dehydrogenase and catalase deficiencies. Therefore it is recommended that these enzymes are determined before therapy. For monitoring of rasburicase therapy the determination of serum uric acid concentration is used. More than 95 per cent of Hungarian clinical laboratories are using the uricate oxidase/peroxidase reactions and hydrogen peroxide measurements in the uric acid assays. These assays may be interfered by ascorbic acid and hydrogen peroxide which is generated by rasburicase either in vivo or in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708312     DOI: 10.1556/OH.2008.28422

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  3 in total

1.  Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.

Authors:  Rodrigo Lopes da Silva
Journal:  Int J Clin Pharm       Date:  2011-04-26

Review 2.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

3.  What Is the Biological Function of Uric Acid? An Antioxidant for Neural Protection or a Biomarker for Cell Death.

Authors:  Dequan Liu; Yu Yun; Dechun Yang; Xinyu Hu; Xianxiang Dong; Nan Zhang; Lumei Zhang; Hua Yin; Weigang Duan
Journal:  Dis Markers       Date:  2019-01-10       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.